Your email has been successfully added to our mailing list.

×
0.00462427745664751 0.00924855491329481 0.0208092485549133 0.0173410404624278 0.0520231213872832 0.0682080924855491 0.0641618497109826 0.113294797687861
Stock impact report

Cytokinetics plunges 19% after Phase 2 trial of ALS drug fails to meet endpoints [MarketWatch]

Cytokinetics, Incorporated (CYTK) 
Last cytokinetics, incorporated earnings: 3/3 04:00 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.cytokinetics.com/investor-overview
Company Research Source: MarketWatch
Cytokinetics plunges 19% after Phase 2 trial of ALS drug fails to meet endpoints Shares of biotech Cytokinetics Inc. CYTK, -3.50% plunged 19% in premarket trade Monday after the company announced that a Phase 2 study of its amyotrophic lateral sclerosis drug did not show a meaningful difference in respiratory function, muscle strength or daily living measures compared with placebo. After 12 weeks on the drug, called reldesemtiv, patients did not show a statistically-significant difference in symptoms at three different dosage points when compared with patients on a placebo, though a post-hoc analysis grouping all treatment groups together showed improvement in daily living compared with placebo. Shares of Cytokinetics have gained 40% in the year to date, while the S&P 500 SPX, -1.20% has gained 17.5%. Have breaking news sent to your inbox. Subscribe to MarketWatch's free Bulletin emails. Sign up here. Show less Read more
Impact Snapshot
Event Time:
CYTK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for CYTK alerts
Opt-in for
CYTK alerts

from News Quantified
Opt-in for
CYTK alerts

from News Quantified